Publications

British journal of pharmacology

Effects of cytochrome P450 3A (CYP3A) and the drug transporters P-glycoprotein (MDR1/ABCB1) and MRP2 (ABCC2) on the pharmacokinetics of lopinavir.

01-07-2010

Human antibodies

Pharmacokinetics of rituximab in patients with CD20 positive B-cell malignancies.

18-06-2010

British journal of clinical pharmacology

Population pharmacokinetics of intravenously and orally administered docetaxel with or without co-administration of ritonavir in patients with advanced cancer.

01-05-2010

Investigational new drugs

Two-stage model-based clinical trial design to optimize phase I development of novel anticancer agents.

01-02-2010

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences

A validated assay for the quantitative analysis of vatalanib in human EDTA plasma by liquid chromatography coupled with electrospray ionization tandem mass spectrometry.

01-11-2009

The oncologist

Pharmacokinetics of gemcitabine and metabolites in a patient with double-sided nephrectomy: a case report and review of the literature.

01-09-2009

Clinical cancer research : an official journal of the American Association for Cancer Research

Coadministration of ritonavir strongly enhances the apparent oral bioavailability of docetaxel in patients with solid tumors.

15-06-2009

Cancer chemotherapy and pharmacology

Carboplatin dosing in overweight and obese patients with normal renal function, does weight matter?

01-06-2009

Investigational new drugs

Application of population pharmacokinetic modeling in early clinical development of the anticancer agent E7820.

01-04-2009

Acta oncologica (Stockholm, Sweden)

Persistent neuropathy after treatment with cisplatin and oxaliplatin.

25-03-2009

Cancer chemotherapy and pharmacology

Carbamazepine induces bioactivation of cyclophosphamide and thiotepa.

01-02-2009

Journal of pharmacokinetics and pharmacodynamics

Covariate-based dose individualization of the cytotoxic drug indisulam to reduce the risk of severe myelosuppression.

01-02-2009

Cancer biotherapy & radiopharmaceuticals

A simple and safe method for 131I radiolabeling of rituximab for myeloablative high-dose radioimmunotherapy.

01-02-2009

Therapeutic drug monitoring

Pharmacokinetics of cyclophosphamide and thiotepa in a conventional fractionated high-dose regimen compared with a novel simplified unfractionated regimen.

01-02-2009

Cancer treatment reviews

An overview of the relations between polymorphisms in drug metabolising enzymes and drug transporters and survival after cancer drug treatment.

01-02-2009

Cancer chemotherapy and pharmacology

Altered cyclophosphamide and thiotepa pharmacokinetics in a patient with moderate renal insufficiency.

01-01-2009

British journal of clinical pharmacology

Polymorphisms of drug-metabolizing enzymes (GST, CYP2B6 and CYP3A) affect the pharmacokinetics of thiotepa and tepa.

01-01-2009

Clinical drug investigation

Ciprofloxacin strongly inhibits clozapine metabolism: two case reports.

11-12-2008

Pharmacogenetics and genomics

Relations between polymorphisms in drug-metabolising enzymes and toxicity of chemotherapy with cyclophosphamide, thiotepa and carboplatin.

01-11-2008

British journal of clinical pharmacology

Population pharmacokinetic and pharmacodynamic analysis to support treatment optimization of combination chemotherapy with indisulam and carboplatin.

01-10-2008

BMC clinical pharmacology

Long-term platinum retention after treatment with cisplatin and oxaliplatin.

17-09-2008

Antimicrobial agents and chemotherapy

Pharmacokinetics of miltefosine in Old World cutaneous leishmaniasis patients.

01-08-2008

Clinical pharmacokinetics

Population pharmacokinetics and pharmacodynamics for treatment optimization in clinical oncology.

10-07-2008

Anti-cancer drugs

The effects of sulfur-containing compounds and gemcitabine on the binding of cisplatin to plasma proteins and DNA determined by inductively coupled plasma mass spectrometry and high performance liquid chromatography-inductively coupled plasma mass spectrometry.

01-07-2008

Clinical pharmacology and therapeutics

PK/PD model of indisulam and capecitabine: interaction causes excessive myelosuppression.

01-06-2008

Pharmacogenetics and genomics

Influence of polymorphisms of drug metabolizing enzymes (CYP2B6, CYP2C9, CYP2C19, CYP3A4, CYP3A5, GSTA1, GSTP1, ALDH1A1 and ALDH3A1) on the pharmacokinetics of cyclophosphamide and 4-hydroxycyclophosphamide.

01-06-2008

British journal of cancer

A dose-escalation study of indisulam in combination with capecitabine (Xeloda) in patients with solid tumours.

22-04-2008

Clinical pharmacokinetics

Population pharmacokinetics and pharmacodynamics of doxorubicin and cyclophosphamide in breast cancer patients: a study by the EORTC-PAMM-NDDG.

22-11-2007

Clinical cancer research : an official journal of the American Association for Cancer Research

Population pharmacokinetics and pharmacodynamics of paclitaxel and carboplatin in ovarian cancer patients: a study by the European organization for research and treatment of cancer-pharmacology and molecular mechanisms group and new drug development group.

01-11-2007

British journal of clinical pharmacology

Safety and pharmacology of paclitaxel in patients with impaired liver function: a population pharmacokinetic-pharmacodynamic study.

01-11-2007

Cancer chemotherapy and pharmacology

Novel paclitaxel formulations for oral application: a phase I pharmacokinetic study in patients with solid tumours.

01-10-2007

International archives of occupational and environmental health

Monitoring of platinum surface contamination in seven Dutch hospital pharmacies using inductively coupled plasma mass spectrometry.

01-08-2007

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences

Simultaneous quantification of cyclophosphamide and its active metabolite 4-hydroxycyclophosphamide in human plasma by high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry (LC-MS/MS).

01-07-2007

Clinical cancer research : an official journal of the American Association for Cancer Research

CYP2C9 and CYP2C19 polymorphic forms are related to increased indisulam exposure and higher risk of severe hematologic toxicity.

15-05-2007

Pharmaceutical research

Assessment of performance of manufacturing procedures in a unit for production of investigational anticancer agents, using a mixed effects analysis.

01-03-2007

Clinical cancer research : an official journal of the American Association for Cancer Research

Flat dosing of carboplatin is justified in adult patients with normal renal function.

01-11-2006

British journal of cancer

Phase II and pharmacological study of oral paclitaxel (Paxoral) plus ciclosporin in anthracycline-pretreated metastatic breast cancer.

09-10-2006

Journal of pharmacokinetics and pharmacodynamics

A semi-physiological population pharmacokinetic model describing the non-linear disposition of indisulam.

01-10-2006

Clinical cancer research : an official journal of the American Association for Cancer Research

Pharmacogenetic screening of CYP3A and ABCB1 in relation to population pharmacokinetics of docetaxel.

01-10-2006

Nederlands tijdschrift voor geneeskunde

[Defining trials of medicinal products according to the revised Dutch Medical Research in Human Subjects Act (WMO)].

23-09-2006

British journal of cancer

A novel self-microemulsifying formulation of paclitaxel for oral administration to patients with advanced cancer.

18-09-2006

Basic & clinical pharmacology & toxicology

Interactions of serum albumin, valproic acid and carbamazepine with the pharmacokinetics of phenytoin in cancer patients.

01-08-2006

British journal of clinical pharmacology

Determinants of the elimination of methotrexate and 7-hydroxy-methotrexate following high-dose infusional therapy to cancer patients.

01-07-2006

Drug metabolism and disposition: the biological fate of chemicals

Saturable binding of indisulam to plasma proteins and distribution to human erythrocytes.

01-06-2006

British journal of cancer

High exposures to bioactivated cyclophosphamide are related to the occurrence of veno-occlusive disease of the liver following high-dose chemotherapy.

08-05-2006

Therapeutic drug monitoring

Population pharmacokinetics of cyclophosphamide and its metabolites 4-hydroxycyclophosphamide, 2-dechloroethylcyclophosphamide, and phosphoramide mustard in a high-dose combination with Thiotepa and Carboplatin.

01-12-2005

Clinical pharmacokinetics

Clinical pharmacokinetics of cyclophosphamide.

20-10-2005

Cancer chemotherapy and pharmacology

Aprepitant inhibits cyclophosphamide bioactivation and thiotepa metabolism.

01-10-2005

Investigational new drugs

Semi-physiological model describing the hematological toxicity of the anti-cancer agent indisulam.

01-06-2005

Therapeutic drug monitoring

Sparse sampling design for therapeutic drug monitoring of sequentially administered cyclophosphamide, thiotepa, and carboplatin (CTC).

01-06-2005